Why the study?
Do adrenoceptor antagonists inhibit platelet aggregation and thromboxane A2 generation in normal human platelet-rich plasma in vitro?
Population
Normal human platelet-rich plasma in vitro
Design
Preclinical
Authors
Loading...
In vitro data should not change practice; leaves open whether select agents confer clinical antiplatelet benefits.
Do adrenoceptor antagonists inhibit platelet aggregation and thromboxane A2 generation in normal human platelet-rich plasma in vitro?
Certain adrenoceptor antagonists (labetalol, pindolol, propranolol) possess antiplatelet and thromboxane-inhibiting properties in vitro, which may offer clinical benefits in vascular disease.
Greer et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: